PULSE BIOSCIENCES INC (PLSE)
US74587B1017 - Common Stock
Overall PLSE gets a fundamental rating of 3 out of 10. We evaluated PLSE against 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for PLSE as it has an excellent financial health rating, but there are worries on the profitability. PLSE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year PLSE has reported negative net income.
In the past year PLSE has reported a negative cash flow from operations.
PLSE had negative earnings in each of the past 5 years.
In the past 5 years PLSE always reported negative operating cash flow.
1.2 Ratios
PLSE has a worse Return On Assets (-49.58%) than 66.84% of its industry peers.
Looking at the Return On Equity, with a value of -58.30%, PLSE is in line with its industry, outperforming 47.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.58% | ||
| ROE | -58.3% | ||
| ROIC | N/A |
ROA(3y)-87.94%
ROA(5y)-99.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PLSE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PLSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLSE has more shares outstanding
Compared to 5 years ago, PLSE has more shares outstanding
There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 42.27 indicates that PLSE is not in any danger for bankruptcy at the moment.
PLSE has a Altman-Z score of 42.27. This is amongst the best in the industry. PLSE outperforms 98.40% of its industry peers.
PLSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 42.27 |
ROIC/WACCN/A
WACC9.08%
2.3 Liquidity
A Current Ratio of 11.93 indicates that PLSE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.93, PLSE belongs to the top of the industry, outperforming 95.72% of the companies in the same industry.
PLSE has a Quick Ratio of 11.93. This indicates that PLSE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PLSE (11.93) is better than 96.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.93 | ||
| Quick Ratio | 11.93 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.68% over the past year.
Looking at the last year, PLSE shows a very strong growth in Revenue. The Revenue has grown by 100.00%.
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PLSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLSE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
PLSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PULSE BIOSCIENCES INC
NASDAQ:PLSE (12/26/2024, 4:37:56 PM)
After market: 18.55 -0.18 (-0.96%)18.73
+0.4 (+2.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.02%
Inst Owner Change17.37%
Ins Owners70.88%
Ins Owner Change20.4%
Market Cap1.15B
Analysts43.33
Price Target4.08 (-78.22%)
Short Float %12.28%
Short Ratio12.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 14.56 | ||
| P/tB | 15.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS1.29
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.58% | ||
| ROE | -58.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-87.94%
ROA(5y)-99.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.43% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.93 | ||
| Quick Ratio | 11.93 | ||
| Altman-Z | 42.27 |
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)25.9%
Cap/Depr(5y)34.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y-17.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.34%
OCF growth 3YN/A
OCF growth 5YN/A